Antigen News and Research

RSS

SSEA4+ marker helps identify and isolate precursors of insulin-producing pancreatic cells

For the millions of people worldwide with type 1 diabetes who cannot produce sufficient insulin, the potential to transplant insulin-producing cells could offer hope for a long-term cure. The discovery of a marker to help identify and isolate stem cells that can develop into insulin-producing cells in the pancreas would be a critical step forward and is described in an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc.

22 Aug 2012

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

Enzalutamide extends castration-resistant prostate cancer survival

Enzalutamide treatment significantly improves survival in men with castration-resistant prostate cancer, demonstrate phase III trial results published in TheNew England Journal of Medicine.

20 Aug 2012

UCP2 uncoupling protein occurs mainly in cells of the immune system

When uncoupling proteins are active, mitochondria produce heat instead of ATP. This may be useful under certain circumstances, such as when an animal is hibernating. But non-hibernating animals also have them. Particularly poorly understood is the uncoupling protein UCP2. Elena Pohl and colleagues at the University of Veterinary Medicine, Vienna, show that the protein occurs mainly in cells of the immune system.

18 Aug 2012

Safety net hospitals prepare for changes from health law; Patients hesitant to challenge doctors

Safety-net hospitals – which often provide care to low-income and uninsured populations – are facing reduced federal and state support for uncompensated care under the Affordable Care Act. However, this study points out that 23 million people will remain uninsured and continue to need care from the hospitals.

18 Aug 2012

Dendritic cells protect against MS in mouse model

In multiple sclerosis, the immune system attacks nerves in the brain and spinal cord, causing movement problems, muscle weakness and loss of vision. Immune cells called dendritic cells, which were previously thought to contribute to the onset and development of multiple sclerosis, actually protect against the disease in a mouse model, according to a study published by Cell Press in the August issue of the journal Immunity.

17 Aug 2012

Combination of Zelboraf and immunotherapy increases tumor responses and survival in MM

Combining the recently approved BRAF inhibitor, Zelboraf with an engineered T cell immunotherapy to treat metastatic melanoma significantly increased tumor responses and survival in an animal model, researchers at UCLA's Jonsson Comprehensive Cancer Center have shown.

16 Aug 2012

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.

16 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Genocea commences GEN-003 Phase 1/2a study in moderate-to-severe HSV-2 infection

Genocea Biosciences announced today that it has initiated a Phase 1/2a clinical study with its lead candidate, GEN-003. GEN-003 is an investigational vaccine designed to stimulate T cell and B cell immune responses to potentially reduce the frequency and severity of clinical outbreaks associated with moderate-to-severe Herpes Simplex Virus type 2 (HSV-2) infection.

16 Aug 2012

Therapeutic breaks for prostate cancer patients

Men with advanced prostate cancer receiving androgen-deprivation therapy may be better off being treated intermittently rather than on a continuous basis, show study findings.

15 Aug 2012

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that it conducted a formal clinical guidance meeting with the U.S. FDA to determine the most expeditious U.S. registration pathway for BiovaxID, its personalized cancer vaccine for the consolidation treatment of follicular non-Hodgkin's lymphoma.

15 Aug 2012

CD4 T cells orchestrate inflammatory attack on the artery wall

Most people probably know that heart disease remains the nation's No. 1 killer. But what many may be surprised to learn is that cholesterol has a major accomplice in causing dangerous arterial plaque buildup that can trigger a heart attack. The culprit? Inflammatory cells produced by the immune system.

15 Aug 2012

Spectrum Pharmaceuticals initiates enrollment in Phase 2b ozarelix study for prostate cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.

15 Aug 2012

Researchers identify key element in the development of Burkitt lymphoma

Burkitt lymphoma is a malignant, fast-growing tumor that originates from a subtype of white blood cells called B lymphocytes of the immune system and often affects internal organs and the central nervous system. Now Dr. Sandrine Sander and Professor Klaus Rajewsky of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have identified a key element that transforms the immune cells into malignant lymphoma cells.

14 Aug 2012

NIH awards ADi Phase II SBIR grant to scan Plasmodium falciparum proteome for protective antigens

Antigen Discovery, Inc. today announced that it has received a Phase II Small Business Innovation and Research award from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The three-year award, totaling approximately $ 2.5 million, is a continuation of a Phase I SBIR grant to scan the Plasmodium falciparum proteome for protective antigens.

13 Aug 2012

Combination of novel drug therapy and PSA test can effectively detect prostate cancer

Researchers have successfully developed and tested a new prostate cancer screening method that uses the combined power of a novel drug therapy and changes in PSA levels over time to identify men with a high PSA who are more likely to have aggressive prostate cancer despite negative biopsies.

12 Aug 2012

PharmAthene receives clinical hold order from FDA for SparVax rPA anthrax vaccine program

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today it has received notification from the U.S. Food and Drug Administration (FDA) that its SparVax rPA anthrax vaccine program has been placed on clinical hold.

12 Aug 2012

New HIV test helps researchers determine incidence, whether prevention strategies work

The Centers for Disease Control and Prevention (CDC) has developed a new HIV test, called the Limiting Antigen Avidity Enzyme Immunoassay, that can tell whether a person contracted the virus within the last 141 days, "hugely important information for researchers, who need to know whether fewer people are becoming newly infected with HIV to determine whether a prevention program is working," the Wall Street Journal's "Health Blog" reports.

9 Aug 2012

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

ImmunoCellular Therapeutics announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy.

9 Aug 2012

Antigen News and Research

SSEA4+ marker helps identify and isolate precursors of insulin-producing pancreatic cells

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Enzalutamide extends castration-resistant prostate cancer survival

UCP2 uncoupling protein occurs mainly in cells of the immune system

Safety net hospitals prepare for changes from health law; Patients hesitant to challenge doctors

Dendritic cells protect against MS in mouse model

Combination of Zelboraf and immunotherapy increases tumor responses and survival in MM

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Genocea commences GEN-003 Phase 1/2a study in moderate-to-severe HSV-2 infection

Therapeutic breaks for prostate cancer patients

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

CD4 T cells orchestrate inflammatory attack on the artery wall

Spectrum Pharmaceuticals initiates enrollment in Phase 2b ozarelix study for prostate cancer

Researchers identify key element in the development of Burkitt lymphoma

NIH awards ADi Phase II SBIR grant to scan Plasmodium falciparum proteome for protective antigens

Combination of novel drug therapy and PSA test can effectively detect prostate cancer

PharmAthene receives clinical hold order from FDA for SparVax rPA anthrax vaccine program

New HIV test helps researchers determine incidence, whether prevention strategies work

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News